Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).